The Approval Process in Action

Life Sciences Tools & DiagnosticsMedical DevicesRegenerative MedicineBiotechnology / Pharmaceuticals

Source: The Life Sciences Report and Visual Capitalist (5/1/13)

What catalysts in the drug development process move biotech company stocks? The savvy investor must know what steps in the U.S. Food and Drug Administration's approval process can propel a stock up or down. From drug discovery to the much-anticipated PDUFA date, The Life Sciences Report and the Visual Capitalist have collaborated on an infographic that describes both the process and related catalysts.

Satellos Bioscience Fast Track Win Fuels DMD Hopes
Source: Streetwise Reports (07/02/2026)

Satellos Bioscience earns FDA Fast Track for SAT-3247 in Duchenne. Explore the market opportunity, clinical catalysts, analyst targets, and what retail investors should know now.

Abivax SA (ABVX:NASDAQ) UC Data Fuels Biotech Opportunity
Source: Streetwise Reports (07/02/2026)

Abivax SA (ABVX:NASDAQ) reports strong obefazimod maintenance results in ulcerative colitis. Explore sector growth, analyst targets, catalysts, and what it means for investors.

DarioHealth (DRIO) Expands Reach via Beluga Health Deal
Source: Streetwise Reports (07/01/2026)

DarioHealth (DRIO) integrates its AI platform with Beluga Health's network to scale provider-backed care. Discover growth catalysts, analyst targets, and investor considerations.

Viking Therapeutics Expands Obesity Pipeline With VK3019 Phase 1
Source: Streetwise Reports (06/27/2026)

Viking Therapeutics launches Phase 1 trial for VK3019 amylin agonist. Discover how this dual-receptor candidate fits the company's expanding obesity strategy and upcoming catalysts for investors.

uniQure Epilepsy Gene Therapy Data Draws Investor Focus
Source: Streetwise Reports (06/26/2026)

uniQure reports early AMT-260 results for refractory MTLE. See the trial data, pipeline catalysts, analyst price target, and what retail investors should watch next.